CD274 and neoplasm: Immunotherapy targeting the PD-1/PD-L1 pathway inhibits the binding of PD-1 to PD-L1, thereby enhancing cancer antigen-specific T cell proliferation, activation, and cytotoxic activity, bringing about an anti-tumor effect [20, 21].